Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry

References

• Owens M. A., Horten B. C., Da Silva M. M. HER2 amplification ratios by fluorescence in‐situ hybridisation and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63–9
   PubMedGoogle Scholar
• Ross J. S., Fletcher J. A., Bloom K. J., et al. Targeted therapy in breast cancer: the HER‐2/neu gene and protein. Mol Cell Proteomics 2004; 3: 379–98
   PubMed Web of Science ®Google Scholar
• van de Vijver M. J., Mooi W. J., Peterse J. L., et al. Amplification and over‐expression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 1988; 2: 111–4
   Google Scholar
• Bilous M., Ades C., Armes J., et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast 2003; 12: 92–8
   PubMed Web of Science ®Google Scholar
• Gusterson B. A., Gelber R. D., Goldhirsch R. N., et al. Prognostic importance of c‐erbB‐2 expression in breast cancer. J Clin Oncol 1992; 10: 1049–56
   PubMed Web of Science ®Google Scholar
• Hynes N. R., Stern D. F. The biology of erbB‐2/neu/HER‐2 and its role in cancer. Biochim Biophys Acta 1994; 1198: 165–84
   PubMed Web of Science ®Google Scholar
• King C. R., Kraus M. H., Aaronsen S. A. Amplification of a novel c‐erbB‐related gene in a human mammary carcinoma. Science 1985; 229: 974–76
   PubMed Web of Science ®Google Scholar
• Ménard S., Fortis S., Castiglioni F., et al. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61((Suppl 2))67–72
   PubMed Web of Science ®Google Scholar
• Press M. F., Bernstein L., Thomas P. A., et al. HER‐2/neu gene amplification characterised by fluorescence in‐situ hybridisation: poor prognosis in node‐negative breast carcinomas. J Clin Oncol 1997; 15: 2894–904
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Clark G. M., Wong S. G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER‐2/neu oncogene. Science 1987; 235: 177–82
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Godolphin W., Jones L. A., et al. Studies of the HER2/neu proto‐oncogene in human breast and ovarian cancer. Science 1989; 244: 707–12
   PubMed Web of Science ®Google Scholar
• Slamon D. J., Leyland‐Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92
   PubMed Web of Science ®Google Scholar
• Marty M., Cognetti F., Maraninchi D., et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2‐positive metastatic breast cancer given as first‐line treatment: results of a randomized phase II trial (M77001). J Clin Oncol 2005; 23: 4265–74
   PubMed Web of Science ®Google Scholar
• Barnes D. M., Bartkova J., Camplejohn R. S., et al. Overexpression of the c‐erbB‐2 oncogene: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?. Eur J Cancer 1992; 28: 644–8
   PubMed Web of Science ®Google Scholar
• Chong D., Cooke T. G., Reeves J. R., et al. Quantitation of EGFR and c‐erbB‐2 expression in preinvasive compared to invasive breast cancer. Eur J Cancer 1999; 35((Suppl 4))S203, (Abstr 792A)
   Web of Science ®Google Scholar
• Piccart‐Gebhart M. First results of the HERA trial. Oral presentation for late breaking abstracts. Scientific Symposium: Advances in Monoclonal Antibody Therapy for Breast Cancer. American Society of Clinical Oncologists Annual Meeting, OrlandoUSA, May 13–17, 2005
   Google Scholar
• Perez E. A. Further analysis of NCCTG‐N9831. Oral presentation for late breaking abstracts. Scientific Symposium: Advances in Monoclonal Antibody Therapy for Breast Cancer. American Society of Clinical Oncologists Annual Meeting, OrlandoUSA, May 13–17, 2005
   Google Scholar
• Romond E. H., Perez E. A., Bryant J., et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER2‐positive operable breast cancer: combined analysis of NSABP‐B31/NCCTG‐N9831. Oral presentation for late breaking abstracts. Scientific Symposium: Advances in Monoclonal Antibody Therapy for Breast Cancer. American Society of Clinical Oncologists Annual Meeting, OrlandoUSA, May 13–17, 2005
   Google Scholar
• van der Vijver M. Emerging technologies for HER2 testing. Oncology 2002; 62((Suppl 1))33–8
   PubMed Web of Science ®Google Scholar
• Tanner M., Gancberg D., Di Leo A., et al. Chromogenic in situ hybridisation: a practical alternative for fluorescence in situ hybridisation to detect HER‐2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000; 157: 1467–72
   PubMed Web of Science ®Google Scholar
• Zhao J., Wu R., Au A., et al. Determination of HER2 gene amplification by chromogenic in‐situ hybridisation (CISH) in archival breast carcinoma. Mod Pathol 2002; 15: 657–65
   PubMed Web of Science ®Google Scholar
• Dandachi N., Dietze O., Hauser‐Kronberger C. Chromogenic in‐situ hybridisation: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in achival human breast carcinoma. Lab Invest 2002; 82: 1007–14
   PubMed Web of Science ®Google Scholar
• Arnould L., Denoux Y., MacGrogan G., et al. Agreement between chromogenic in‐situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer 2003; 88: 1587–91
   PubMed Web of Science ®Google Scholar
• Tubbs R., Pettay J., Skacel M., et al. Automated chromogenic in situ hybridisation (CISH) for detection of HER2 gene amplification. USCAP Annual Meeting,. March 22‐28, 2003, (Abstr 212)
   Google Scholar
• Elston C. W., Ellis I. O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology 1991; 19: 403–10
   PubMed Web of Science ®Google Scholar
• van de Vijver M., Rueschoff J., Penault‐Llorca F., et al. Chromogenic in‐situ hybridisation (CISH) compared with FISH and IHC for detection of HER2 gene amplification: an international validation ring study. Breast Cancer Res Treat 2003; 82((Suppl 1)), (Abstr 324)
   Google Scholar
• Gong Y., Gilcrease M., Sneige N. Reliability of chromogenic in situ hybridisation for detecting HER2 gene status in breast cancer: comparison with fluorescence in situ hybridisation and assessment of interobserver reproducibility. Mod Pathol 2005; 18: 1015–21
   PubMed Web of Science ®Google Scholar
• Klein P., Gilkerson E. Pateints with ER+/HER2+ or ER‐/HER2+ tumours derive similar clinical benefit from trastuzumab (Herceptin)‐based therapy for metastatic breast cancer. Proc Am Soc Clin Oncol 2003; 22: 45, (Abstr 179, poster update)
   Google Scholar
• Vogel C. L., Murphy M., Cobleigh M., et al. Relationship of oestrogen receptor (ER) status to clinical benefit in clinical trials of Herceptin. Eur J Cancer 2001; 37((Suppl 6))S160, (Abstr 694, poster update)
   Google Scholar